MENU
+Compare
CGEN
Stock ticker: NASDAQ
AS OF
Jun 6, 11:26 AM (EDT)
Price
$1.72
Change
+$0.01 (+0.58%)
Capitalization
147.56M

CGEN Compugen Ltd Forecast, Technical & Fundamental Analysis

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy... Show more

Industry: #Biotechnology
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for CGEN with price predictions
Jun 05, 2025

CGEN in upward trend: price rose above 50-day moving average on May 23, 2025

CGEN moved above its 50-day moving average on May 23, 2025 date and that indicates a change from a downward trend to an upward trend. In of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 19, 2025. You may want to consider a long position or call options on CGEN as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CGEN just turned positive on May 15, 2025. Looking at past instances where CGEN's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for CGEN crossed bullishly above the 50-day moving average on May 29, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in of 240 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 120 cases where CGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CGEN moved out of overbought territory on June 04, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CGEN broke above its upper Bollinger Band on June 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.800) is normal, around the industry mean (16.332). P/E Ratio (64.000) is within average values for comparable stocks, (59.787). CGEN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.227). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (5.593) is also within normal values, averaging (263.647).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

CGEN is expected to report earnings to fall 25.00% to -5 cents per share on July 31

Compugen Ltd CGEN Stock Earnings Reports
Q2'25
Est.
$-0.06
Q1'25
Missed
by $0.01
Q4'24
Missed
by $0.09
Q3'24
Beat
by $0.11
Q2'24
Beat
by $0.07
The last earnings report on May 19 showed earnings per share of -7 cents, missing the estimate of -7 cents. With 69.05K shares outstanding, the current market capitalization sits at 147.56M.
A.I. Advisor
published General Information

General Information

a maker of drug and diagnostics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
26 Harokmim Street
Phone
+972 37658585
Employees
68
Web
https://www.cgen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JPVZX16.63N/A
N/A
JPMorgan Developed International ValueR2
FGRAX49.50N/A
N/A
Franklin Growth Opportunities A
ABCEX8.98N/A
N/A
AB Emerging Markets Multi-Asset C
AQGIX11.75N/A
N/A
AQR Global Equity I
WWMCX11.05N/A
N/A
Westwood Quality Midcap Institutional

CGEN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with NURPF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then NURPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
+0.58%
NURPF - CGEN
46%
Loosely correlated
N/A
BDTX - CGEN
43%
Loosely correlated
-2.36%
ASPHF - CGEN
41%
Loosely correlated
N/A
ROIV - CGEN
40%
Loosely correlated
-0.18%
ORMP - CGEN
40%
Loosely correlated
-5.70%
More